Loading...
XASXAVH
Market cap301mUSD
Dec 20, Last price  
3.75AUD
1D
1.35%
1Q
22.55%
Jan 2017
75.04%
IPO
-7.63%
Name

AVITA Medical Inc

Chart & Performance

D1W1MN
XASX:AVH chart
P/E
P/S
5.96
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
21.80%
Rev. gr., 5y
39.58%
Revenues
51m
+254.49%
00000000003,352,2682,814,9902,683,133985,6471,002,0071,180,6321,255,17120,667,08714,263,00050,561,006
Net income
-39m
L-6.81%
0000000000-7,590,129-8,092,938-5,147,391-7,866,452-10,271,962-11,511,024-17,206,258-60,901,470-42,030,000-39,168,218
CFO
-28m
L+23.27%
-579,754-1,898,914-6,025,7470-9,830,599-8,973,408-3,691,281-4,687,450-1,619,063-2,924,673-4,266,157-7,249,403-6,924,939-6,407,436-7,938,557-8,557,524-17,510,256-32,960,403-22,747,000-28,041,301
Earnings
Feb 21, 2025

Profile

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
IPO date
Mar 18, 2012
Employees
126
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑062020‑062018‑062017‑062016‑062015‑06
Income
Revenues
50,561
254.49%
Cost of revenue
95,686
Unusual Expense (Income)
NOPBT
(45,125)
NOPBT Margin
Operating Taxes
53
Tax Rate
NOPAT
(45,177)
Net income
(39,168)
-6.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
612
Long-term debt
1,798
Deferred revenue
Other long-term liabilities
3,709
Net debt
(124,315)
Cash flow
Cash from operating activities
(28,041)
CAPEX
(664)
Cash from investing activities
(28,397)
Cash from financing activities
1,322
FCF
(44,480)
Balance
Cash
116,545
Long term investments
10,179
Excess cash
124,197
Stockholders' equity
(374,699)
Invested Capital
503,138
ROIC
ROCE
EV
Common stock shares outstanding
25,000
Price
1.96
-90.45%
Market cap
49,000
-88.23%
EV
(75,315)
EBITDA
(44,290)
EV/EBITDA
1.70
Interest
Interest/NOPBT